drug · small molecule

INLURIYO

updated 3mo ago

by $LLY ELI LILLY & Co🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 4

Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.

all catalysts(0)

nothing on the calendar yet

News(1)

Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.
biopharma_dive · 3mo ago

brand

INLURIYO

generic

IMLUNESTRANT TOSYLATE

MOA

12.1 Mechanism of Action Imlunestrant is an estrogen receptor (ER) antagonist that binds to ERα. In vitro, imlunestrant induced degradation of ERα, leading to inhibition of ER-dependent gene transcription and cellular proliferation in ER+ breast cancer cells. Imlunestrant demonstrated in vitro and in vivo anti-tumor activity in ER+ breast cancer xenograft models, including models with ESR1 mutations.

indication

1 INDICATIONS AND USAGE INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1 )-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. INLURIYO TM is an estrogen receptor antagonist indicated for: treatment of adults with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 45m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

INLURIYO

updated 3mo ago

by $LLY ELI LILLY & Co🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 4

Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.

all catalysts(0)

nothing on the calendar yet

News(1)

Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.
biopharma_dive · 3mo ago

brand

INLURIYO

generic

IMLUNESTRANT TOSYLATE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 45m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

INLURIYO

🐶 often sniffed alongside

all catalysts(0)

News(1)

Report a data issue

comments(0)

INLURIYO

🐶 often sniffed alongside

all catalysts(0)

News(1)

Report a data issue

comments(0)